Between October 2015 and August 2016, Zimbabwe conducted the Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) cross-sectional survey to determine progress toward epidemic control. Of 25,131 eligible adults aged 15–64 years, 20,577 (81.8%) consented to face-to-face questionnaire and biomarker testing in this nationally representative household survey. Home-based rapid HIV testing was performed using Determine, First Response, and STAT-PAK as the tiebreaker. HIV-positive tests were confirmed in a laboratory using Geenius HIV-1/2; viral load (VL) was measured using Roche TaqMan and BioMerieux NucliSENS. Recency of infection was tested using Sedia HIV-1 Limiting Antigen (LAg)-Avidity. Presence of antiretroviral (ARV) drugs was detected using high performance liquid chromatography/mass spectrometry (HPLC/MS). The recent infection testing algorithm included LAg-avidity enzyme immunoassay [normalized optical density (ODn ≤1.5), VL ≥1,000 copies/mL, and absence of ARV drugs]. Weighted annual HIV incidence was compared with United Nations Joint Programme on HIV/AIDS (UNAIDS) Spectrum models estimates. Overall, 26 of 2,901 HIV-seropositive individuals had a recent infection (men, 8; women, 18). Overall weighted annual incidence among persons aged 15–64 years was 0.42% [95% confidence interval (CI): 0.25–0.59] and was 0.44% (95% CI: 0.25–0.62) for those aged 15–49 years, similar to 2016 Spectrum model estimate (0.54%, 95% CI: 0.49–0.66) for this age group. Among persons aged 15–49 years, HIV prevalence was 13.35% (95% CI: 12.71–14.02), estimated HIV-positive individuals were 968,951 (95% CI: 911,473–1,026,430), of these, 41,911 (95% CI: 37,412–44,787) were annual-new infections, and this was similar to 2016 Spectrum estimates. The observed HIV incidence in ZIMPHIA 2015–2016 validated the 2016 Spectrum estimates and Zimbabwe's progress toward epidemic control.

中文翻译：

---

津巴布韦基于人口的 HIV 影响评估调查（2015-2016 年）中的 HIV 发病率与模型估计的比较：流行病控制的进展。

2015 年 10 月至 2016 年 8 月期间，津巴布韦进行了基于津巴布韦人口的 HIV 影响评估 (ZIMPHIA) 横断面调查，以确定在流行病控制方面取得的进展。在 25,131 名 15-64 岁符合条件的成年人中，20,577 (81.8%) 同意在这项具有全国代表性的家庭调查中进行面对面的问卷调查和生物标志物测试。使用“确定”、“第一反应”和“STAT-PAK”作为决胜局进行基于家庭的快速 HIV 检测。在实验室中使用 Geenius HIV-1/2 确认了 HIV 阳性检测；使用 Roche TaqMan 和 BioMerieux NucliSENS 测量病毒载量 (VL)。使用 Sedia HIV-1 限制性抗原 (LAg)-Avidity 测试感染的新近度。使用高效液相色谱/质谱 (HPLC/MS) 检测抗逆转录病毒 (ARV) 药物的存在。最近的感染测试算法包括 LAg 亲和性酶免疫分析 [归一化光密度 (ODn ≤ 1.5)，VL ≥ 1,000 拷贝/mL，并且没有抗病毒药物]。加权的年度 HIV 发病率与联合国艾滋病毒/艾滋病联合规划 (UNAIDS) 频谱模型估计值进行了比较。总体而言，在 2,901 名 HIV 血清阳性个体中，有 26 名最近感染了病毒（男性，8 名；女性，18 名）。15-64 岁人群的总体加权年发病率为 0.42% [95% 置信区间 (CI)：0.25-0.59]，15-49 岁人群为 0.44%（95% CI：0.25-0.62），类似于该年龄组的 2016 年频谱模型估计值 (0.54%, 95% CI: 0.49–0.66)。在 15-49 岁的人群中，HIV 流行率为 13.35%（95% CI：12.71-14.02），估计 HIV 阳性个体为 968,951（95% CI：911,473-1,026,430），其中 41,911（95% CI：37,412） –44, 787) 是年度新感染，这与 2016 年 Spectrum 估计值相似。津巴布韦 2015-2016 年观察到的 HIV 发病率验证了 2016 年的频谱估计和津巴布韦在流行病控制方面的进展。